Ann Lab Med.  2016 Jul;36(4):313-319. 10.3343/alm.2016.36.4.313.

Prognostic Value of Soluble ST2 During Hospitalization for ST-Segment Elevation Myocardial Infarction

• Barbarash
• Gruzdeva O
• Uchasova E
• Dyleva Y
• Belik E
• Akbasheva
• Karetnikova V
• Shilov A

• KMID: 2373550
• DOI: http://doi.org/10.3343/alm.2016.36.4.313

Abstract

BACKGROUND
Studying the role of soluble ST2 (sST2) during hospitalization for myocardial infarction (MI) can be helpful for predicting the course of the hospitalization and development of complications.
METHODS
We included 88 patients with MI (median age, 58 yr). Depending on the course of the hospitalization, the patients were divided into two groups: the favorable (n=58) and unfavorable (n=30) outcome groups. On days 1 and 12 after MI, serum sST2 and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured by ELISA.
RESULTS
On day 1, the concentrations of sST2 and NT-proBNP increased 2.4- and 4.5-fold, compared with the controls. Measurements on day 12 showed a significant decrease in the sST2 level (P=0.001), whereas the NT-proBNP level did not change. On day 1, the sST2 level in the unfavorable outcome group was 2-fold higher than that in the favorable outcome group and 3.7-fold higher than in the controls. On day 12, the marker level decreased in both groups. On day 1, the NT-proBNP level in the unfavorable outcome group was 6.8-fold higher than in the controls and 1.8-fold higher than in the favorable outcome group. On day 12, the level of NT-proBNP remained elevated in both groups. Determining the levels of both sST2 and NT-proBNP increases their diagnostic significance (odds ratio [OR], 1.92; 95% confidence interval [CI], 1.7-3.2; areas under curve [AUC] 0.89; P=0.004).
CONCLUSIONS
The level of sST2 is a more sensitive indicator during MI hospitalization than NT-proBNP.

Keyword

Myocardial infarction; NT-proBNP; sST2

MeSH Terms

Area Under Curve
Case-Control Studies
Electrocardiography
Enzyme-Linked Immunosorbent Assay
Female
Hospitalization
Humans
Logistic Models
Male
Middle Aged
Myocardial Infarction/*diagnosis/diagnostic imaging
Natriuretic Peptide, Brain/blood
Odds Ratio
Peptide Fragments/blood
Prognosis
Proportional Hazards Models
ROC Curve
Receptors, Somatostatin/*blood
Natriuretic Peptide, Brain
Peptide Fragments
Receptors, Somatostatin

Figure

• 

  Fig. 1 Concentration of soluble ST2 and the N-terminal pro-brain natriuretic peptide (NT-proBNP) in the patients on day 1 and day 12 after myocardial infarction.*Compared with the control group (P=0.002 for comparison of sST2 concentrations; P=0.001 for comparison of NT-proBNP concentrations); †Statistically significant differences between groups at day 12 (P=0.001).

Reference

1. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodeling. Lancet. 2006; 367:356–367. PMID: 16443044.

2. Gravning J, Smedsrud MK, Omland T, Eek C, Skulstad H, Aaberge L, et al. Sensitive troponin assays and N-terminal pro-B-type natriuretic peptide in acute coronary syndrome: prediction of significant coronary lesions and long-term prognosis. Am Heart J. 2013; 165:716–724. PMID: 23622908.

3. Ciccone MM, Cortese F, Gesualdo M, Riccardi R, Di Nunzio D, Moncelli M, et al. A novel cardiac bio-marker: ST2: a review. Molecules. 2013; 18:15314–15328. PMID: 24335613.

4. Maries L, Manitiu I. Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). Cardiovasc J Afr. 2013; 7:286–289. PMID: 24217307.

5. Demyanets S, Kaun C, Pentz R, Krychtiuk KA, Rauscher S, Pfaffenberger S, et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol. 2013; 60:16–26. PMID: 23567618.

6. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol. 2007; 179:2551–2555. PMID: 17675517.

7. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009; 2:684–691. PMID: 19919994.

8. Felker GM, Fiuzat M, Thompson V, Shaw LK, Neely ML, Adams KF, et al. Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes. Circ Heart Fail. 2013; 6:1172–1179. PMID: 24103327.

9. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004; 109:2186–2190. PMID: 15117853.

10. Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem. 2012; 58:257–266. PMID: 22096031.

11. Hur M, Kim H, Kim HJ, Yang HS, Magrini L, Marino R, et al. Soluble ST2 has a prognostic role in patients with suspected sepsis. Ann Lab Med. 2015; 35:570–577. PMID: 26354344.

12. Thygesen K, Alpert J, White HD. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Jaffe AS, Apple FS, et al. Universal definition of myocardial infarction. Circulation. 2007; 116:2634–2653. PMID: 17951284.

13. Glanz S. Primer of biostatistics (5th Edition). Europe: McGraw-Hill Education;2001. p. 496.

14. Liang F, Wu J, Garami M, Gardner DG. Mechanical strain increases expression of the brain natriuretic peptide gene in rat cardiac myocytes. J Biol Chem. 1997; 272:28050–28056. PMID: 9346958.

15. He Q, Wang D, Yang XP, Carretero OA, LaPointe MC. Inducible regulation of human brain natriuretic peptide promoter in transgenic mice. Am J Physiol Heart Circ Physiol. 2001; 280:H368–H376. PMID: 11123253.

16. Mathewkutty S, Sethi SS, Aneja A, Shah K, Iyengar RL, Hermann L, et al. Biomarkers after risk stratification in acute chest pain (from the BRIC Study). Am J Cardiol. 2013; 111:493–498. PMID: 23218997.

17. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008; 7:827–840. PMID: 18827826.

18. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008; 117:1936–1944. PMID: 18378613.

19. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm. 2011; 8:22.

20. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007; 117:1538–1549. PMID: 17492053.

21. Januzzi JL, Mebazaa A, Di Somma S. ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel. Am J Cardiol. 2015; 115(7 Suppl):26B–31B.

22. Mueller T, Leitner I, Egger M, Haltmayer M, Dieplinger B. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases. Clin Chim Acta. 2015; 445:155–160. PMID: 25850080.

23. Gruzdeva O, Uchasova E, Belik E, Dyleva Y, Shurygina E, Barbarash O. Lipid, adipokine and ghrelin levels in myocardial infarction patients with insulin resistance. BMC Cardiovasc Disord. 2014; 14:7. PMID: 24433403.

24. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002; 106:2961–2966. PMID: 12460879.

25. Demyanets S, Speidl WS, Tentzeris I, Jarai R, Katsaros KM, Farhan S, et al. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS One. 2014; 9:e95055. PMID: 24751794.